Riederer P - Search Results

1

Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.

Gerlach M, Riederer P, Double KL. Gerlach M, et al. Among authors: riederer p. Parkinsonism Relat Disord. 2008;14 Suppl 2:S185-8. doi: 10.1016/j.parkreldis.2008.04.028. Epub 2008 Jun 27. Parkinsonism Relat Disord. 2008. PMID: 18585086 Review.

2

Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P. Gerlach M, et al. Among authors: riederer p. Neurotox Res. 2003;5(1-2):35-44. doi: 10.1007/BF03033371. Neurotox Res. 2003. PMID: 12832223 Review.

3

The relevance of iron in the pathogenesis of Parkinson's disease.

Götz ME, Double K, Gerlach M, Youdim MB, Riederer P. Götz ME, et al. Among authors: riederer p. Ann N Y Acad Sci. 2004 Mar;1012:193-208. doi: 10.1196/annals.1306.017. Ann N Y Acad Sci. 2004. PMID: 15105267 Review.

4

Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

Riederer P, Gerlach M, Müller T, Reichmann H. Riederer P, et al. Parkinsonism Relat Disord. 2007 Dec;13(8):466-79. doi: 10.1016/j.parkreldis.2007.06.015. Epub 2007 Oct 4. Parkinsonism Relat Disord. 2007. PMID: 17919963 Review.

5

Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stöffler A, Streffer J, Berg D. Gerlach M, et al. Among authors: riederer p. J Neural Transm (Vienna). 2012 Jan;119(1):39-52. doi: 10.1007/s00702-011-0682-x. Epub 2011 Jul 14. J Neural Transm (Vienna). 2012. PMID: 21755462 Free PMC article. Review.

6

Neural degeneration in Parkinson's disease.

Riederer P, Reichmann H, Janetzky B, Sian J, Lesch KP, Lange KW, Double KL, Nagatsu T, Gerlach M. Riederer P, et al. Adv Neurol. 2001;86:125-36. Adv Neurol. 2001. PMID: 11553969 Review. No abstract available.

7

Brain iron pathways and their relevance to Parkinson's disease.

Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G. Berg D, et al. Among authors: riederer p. J Neurochem. 2001 Oct;79(2):225-36. doi: 10.1046/j.1471-4159.2001.00608.x. J Neurochem. 2001. PMID: 11677250 Free article. Review.

8

Potential sources of increased iron in the substantia nigra of parkinsonian patients.

Gerlach M, Double KL, Youdim MB, Riederer P. Gerlach M, et al. Among authors: riederer p. J Neural Transm Suppl. 2006;(70):133-42. doi: 10.1007/978-3-211-45295-0_21. J Neural Transm Suppl. 2006. PMID: 17017520 Review.

9

Genomic aspects of sporadic Parkinson's disease.

Riederer P, Youdim MB, Mandel S, Gerlach M, Grünblatt E. Riederer P, et al. Parkinsonism Relat Disord. 2008;14 Suppl 2:S88-91. doi: 10.1016/j.parkreldis.2008.04.009. Epub 2008 Jun 27. Parkinsonism Relat Disord. 2008. PMID: 18585078 Review.

10

Iron-binding characteristics of neuromelanin of the human substantia nigra.

Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D. Double KL, et al. Among authors: riederer p. Biochem Pharmacol. 2003 Aug 1;66(3):489-94. doi: 10.1016/s0006-2952(03)00293-4. Biochem Pharmacol. 2003. PMID: 12907248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

839 results

Search Page

Filters